Funded Researchers

2018-2019 Funding Cycle - Current Research Grant Recipients

To download a PDF with the lay abstract for each research grant recipient, click here.

Daniel Herranz Benito, Ph.D. – Rutgers Cancer Institute
Dissecting the role of PKM2 in NOTCH1-induced T-ALL

Kishore Challagundla, Ph.D. – University of Nebraska Medical Center
Exosomic miRNAs and PD-L1 in AML Therapy Resistance

Shunji Egusa, Ph.D. – The University of North Carolina Charlotte
Au nano-linker: Turning standard AML drugs into lineage-targeted therapeutics

Jin Seon Im, M.D., Ph.D. – The University of Texas MD Anderson Cancer Center
Third Party Gene-Modified iNK t cells to Prevent GVHD and Relapse after Transplantion

Matthew Mei, M.D. – City of Hope National Medical Center
Overcoming Resistance to Chemotherapeutic Intervention in Leukemia and Lymphoma

Esther A. Obeng, M.D., Ph.D. – St. Jude Children's Research Hospital
Uncovering how SF3B1 and TET2 mutations cooperate to develop aggressive MDS

Chintan Parekh, M.D. – Children's Hospital Los Angeles
Molecular characterization of minimal residual disease cells in pediatric ALL

Paulina Podszywalow-Bartnicka, Ph.D. – Nencki Institution of Experimental Biology (Warsaw, Poland)
Synthetic lethality in leukemia - effect of PARP1 inhibitors in bone marrow niche

Brittany Knick Ragon, M.D. – Levine Cancer Institute
Identification of molecular and genetic determinants of response to hypomethylation agents in AML

Russel J. H. Ryan, M.D. – University of Michigan
Identifying Unique /myc Enhancer Dependencies in B-Lymphoblastic Leukemia

Cristina Scielzo, Ph.D. – IRCCS (Milan, Italy)
Decipher the dynamic expression of targetable signalling pathways in CLL tissues by exploiting new 3D models

Yue Wei, Ph.D. – The University of Texas MD Anderson Cancer Center
Characterize the pathological role and therapeutic potential of histone demethylase KDM6B in MDS